Brief: CSPC Pharmaceutical Logs FY Net Income Attributable RMB 3,882.1 Mln
25/03/2026 04:21
March 25 (Reuters) - CSPC Pharmaceutical Group Ltd 1093.HK: RECOMMENDED A FINAL DIVIDEND OF HK15 CENTS PER SHARE FOR 2025 FY NET INCOME ATTRIBUTABLE RMB 3,882.1 MILLION FY REVENUE RMB 20,583.7 MILLION Further company coverage: [ ] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines